Peter Parker

Founder and CEO at BioInnovation, Director at LabCentral, Former General Partner at Ampersand Ventures, Co-Founder and Director at LabCentral. Peter Parker was the founding CEO and President of Cequent Pharmaceuticals until its merger into Marina Biotechnology [NASDAQ: MRNA], valued at $46MM. In this function, he led Cequent from seed-stage to a clinical stage RNAi Therapeutic company with its first therapeutic candidate about to enter clinical trials. This drug for the indication of Familial Adenomatous Polyposis will be the first-ever oral RNAi therapeutic world-wide. Peter is a close advisor to the ViThera team on finance, business and licensing questions. For 18 years, Peter Parker was responsible for the Life Science portfolio at Ampersand Ventures, a Boston based Venture Capital Firm. He has served as a Director of numerous biotechnology and specialty chemical companies including ACLARA Biosciences, Tomah Products, VITEX, Magellan Biosciences, Dynex and Pentose Pharmaceuticals and as Chairman of Alexis, NOVEX, CoPharma, Huntington Laboratories, Protein Ingredient Technologies, Cyclis Pharmaceuticals, Nanodyne, Panacos Pharmaceuticals, AC Tech, Boston Heart Lab and TekCel. Prior to Ampersand, Peter spent fourteen years at AMAX, Inc. where he was President of Climax Performance Materials Corporation and Corporate Director of Research and Development. He holds B.S. and M.S. degrees from Columbia University.